CLDX Valuation

Celldex Therapeutics Inc

Add to Watchlist

Advanced Chart

23.870

+1.51(6.753%)1D

Overview
Forecast
Valuation
Earnings

CLDX Relative Valuation

CLDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLDX is overvalued; if below, it's undervalued.

Historical Valuation

Celldex Therapeutics Inc (CLDX) is now in the Fair zone, suggesting that its current forward PS ratio of 364.95 is considered Fairly compared with the five-year average of -13.65. The fair price of Celldex Therapeutics Inc (CLDX) is between 13.78 to 42.46 according to relative valuation methord.

Relative Value

Fair Zone

13.78-42.46

Current Price：22.36

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.11

P/B

Median3y

4.05

Median5y

4.29

-11.84

FCF Yield

Median3y

-7.13

Median5y

-6.27

Competitors Valuation Multiple

The average P/S ratio for CLDX's competitors is 72.65, providing a benchmark for relative valuation. Celldex Therapeutics Inc Corp (CLDX) exhibits a P/S ratio of 359.25, which is 394.47% above the industry average. Given its robust revenue growth of 345.51%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLDX.O

Celldex Therapeutics Inc

359.25

Average P/S: 72.65

345.51%